- 1.
Hirota S, Isozaki K, Moriyama Y et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577 - 80. [PubMed][CrossRef]
- 2.
Joensuu H, Roberts PJ, Sarlomo-Rikala M et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344: 1052 - 6. [PubMed][CrossRef]
- 3.
Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472 - 80. [PubMed][CrossRef]
- 4.
DeMatteo RP, Lewis JJ, Leung D et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231: 51 - 8. [PubMed][CrossRef]
- 5.
Hompland I, Bruland ØS, Hølmebakk T et al. Prediction of long-term survival in patients with metastatic gastrointestinal stromal tumor: analysis of a large, single-institution cohort. Acta Oncol 2017; 56: 1317 - 23. [PubMed][CrossRef]
- 6.
Joensuu H, Eriksson M, Sundby Hall K et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 2012; 307: 1265 - 72. [PubMed][CrossRef]
- 7.
Casali PG, Abecassis N, Bauer S et al. Gastrointestinal stromal tumours: ESMO-EUROCAN clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; doi: 10.1093/annonc/mdy095. [PubMed][CrossRef]
- 8.
Søreide K, Sandvik OM, Søreide JA et al. Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies. Cancer Epidemiol 2016; 40: 39 - 46. [PubMed][CrossRef]
- 9.
Fletcher CDM, Bridge JA, Hogendoorn PCW et al. WHO Classification of tumours of soft tissue and bone. 4. utg. Lyon: IARC, 2013. (Vol. 5 i serien: WHO/IARC Classification of tumours).
- 10.
Joensuu H, Vehtari A, Riihimäki J et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol 2012; 13: 265 - 74. [PubMed][CrossRef]
- 11.
Steigen SE, Eide TJ, Wasag B et al. Mutations in gastrointestinal stromal tumors–a population-based study from Northern Norway. APMIS 2007; 115: 289 - 98. [PubMed][CrossRef]
- 12.
Hølmebakk T, Bjerkehagen B, Boye K et al. Definition and clinical significance of tumour rupture in gastrointestinal stromal tumours of the small intestine. Br J Surg 2016; 103: 684 - 91. [PubMed][CrossRef]
- 13.
Hølmebakk T, Hompland I, Bjerkehagen B et al. Recurrence-free survival after resection of gastric gastrointestinal stromal tumors classified according to a strict definition of tumor rupture: A population-based study. Ann Surg Oncol 2018; 25: 1133 - 9. [PubMed][CrossRef]
- 14.
Boye K, Berner JM, Hompland I et al. Genotype and risk of tumour rupture in gastrointestinal stromal tumour. Br J Surg 2018; 105: e169 - 75. [PubMed][CrossRef]
- 15.
Patrikidou A, Chabaud S, Ray-Coquard I et al. Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial. Ann Oncol 2013; 24: 1087 - 93. [PubMed][CrossRef]
- 16.
Hompland I, Bruland ØS. Can imatinib be safely withdrawn in patients with surgically resected metastatic GIST? Anticancer Res 2015; 35: 5759 - 65. [PubMed]
- 17.
Wardelmann E, Thomas N, Merkelbach-Bruse S et al. Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. Lancet Oncol 2005; 6: 249 - 51. [PubMed][CrossRef]
- 18.
Hompland I, Bruland ØS, Ubhayasekhera K et al. Clinical implications of repeated drug monitoring of imatinib in patients with metastatic gastrointestinal stromal tumour. Clin Sarcoma Res 2016; 6: 21. [PubMed][CrossRef]
- 19.
Revheim M-E, Hole KH, Bruland ØS et al. Multimodal functional imaging for early response assessment in GIST patients treated with imatinib. Acta Oncol 2014; 53: 143 - 8. [PubMed][CrossRef]
- 20.
Tielen R, Verhoef C, van Coevorden F et al. Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile? World J Surg Oncol 2012; 10: 111. [PubMed][CrossRef]
()
Denne artikkelen ble publisert for mer enn 12 måneder siden, og vi har derfor stengt for nye kommentarer.